Microbot Med Inc Stock Price, News & Analysis

Microbot Medical (NASDAQ:MBOT) announces that CEO Harel Gadot will participate in a livestream interview on Benzinga All Access on September 24, 2025, at 10:45am ET. The discussion will focus on the company's recent FDA 510(k) clearance for the LIBERTY® Endovascular Robotic System, which was received on September 8, 2025.

During the interview, Mr. Gadot will outline the company's commercialization strategy for LIBERTY® in the U.S. market and discuss how this innovative system aims to transform the peripheral endovascular space.

Microbot Medical (Nasdaq: MBOT) announced the first closing of its preferred investment options exercise, which could generate up to $92.2 million in total gross proceeds. The transaction includes $25.2 million from the first closing and expected $4 million from the second closing, with potential additional proceeds of $63 million if new short-term series J preferred investment options are fully exercised.

The first closing involves 12,064,627 shares at exercise prices of $1.50-$2.13 per share, while the second closing will include 1,924,488 shares at $2.10 per share. New series J options will have a $4.50 exercise price. Proceeds will fund the LIBERTY® Robotic System development, potential acquisitions, and working capital.

Microbot Medical (NASDAQ: MBOT) has announced significant preferred investment options exercise agreements that could generate up to $92.2 million in gross proceeds. The transaction will occur in two closings: a first closing of $25.2 million expected around September 16, 2025, and a second closing of $4 million by October 15, 2025.

The deal involves issuing new unregistered short-term series J preferred investment options to purchase up to 13,989,115 shares of common stock. These new options will have an exercise price of $4.50 per share, becoming exercisable six months after issuance with a two-year term, potentially generating an additional $63 million if fully exercised.

The company plans to use the proceeds for the development and commercialization of its LIBERTY® Robotic System, potential acquisitions, expansion of IP applications, and working capital.

Microbot Medical (NASDAQ:MBOT) announced that CEO Harel Gadot will present at the H.C. Wainwright Annual Investor Conference, focusing on the company's recent FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. The LIBERTY® System is notable as the first single-use, remotely operated robotic system designed for peripheral endovascular procedures.

The presentation is scheduled for September 9th at 9:00am ET and will be available via webcast through the company's website.

Microbot Medical (Nasdaq: MBOT) has achieved a significant milestone with FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The company plans to commence commercialization in Q4 2025, targeting an initial U.S. market of approximately 2.5 million annual peripheral vascular procedures.

The LIBERTY® pivotal study demonstrated remarkable results, including 100% success in robotic navigation to target, zero device-related adverse events, and a 92% reduction in physician radiation exposure. The system's remote design aims to improve ergonomics and reduce physical strain on healthcare providers while enhancing procedure efficiency and lowering costs.

Microbot Medical (Nasdaq: MBOT) has secured a significant new U.S. patent for its LIBERTY® Endovascular Robotic System, expanding its potential market applications. The patent covers a modular robotic surgical system with interchangeable tool-receiver units, strengthening the company's IP portfolio which now includes 12 granted patents globally and 57 pending applications.

This development could enable LIBERTY® to expand beyond its initial focus on peripheral endovascular procedures (estimated at 2.5 million annual procedures in the U.S.) to potentially reach over 6 million annual endovascular procedures. The company is currently awaiting FDA 510(k) clearance for LIBERTY®, which is notable for being the first fully disposable robotic system in its field.

Microbot Medical (Nasdaq: MBOT) has secured a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority (IIA). The funding will enhance the company's manufacturing capabilities as it prepares for the potential commercialization of its LIBERTY® Endovascular Robotic System, which is currently awaiting FDA marketing clearance.

The IIA's decision was influenced by several factors, including the target market size, competitive advantages of the single-use disposable robot, regulatory status, and expected healthcare benefits. The LIBERTY® System is currently an investigational device pending FDA 510(k) clearance and is not available for sale in the U.S.

Microbot Medical (NASDAQ:MBOT) has appointed Christina Bailey as its new Vice President of Sales to strengthen its commercial leadership ahead of the anticipated LIBERTY® Endovascular Robotic System launch. Bailey, a two-time U.S. Olympian and gold medalist, brings 20 years of medical device sales experience from prominent companies including Boston Scientific, Abbott, Stryker, and Intuitive Surgical.

As former VP of US Sales at Endologix, Bailey demonstrated success in building and scaling sales teams. She will report directly to CEO Harel Gadot and will be responsible for establishing the sales team for LIBERTY®, which is currently pending FDA 510(k) clearance.

Microbot Medical (NASDAQ: MBOT) announced its participation in the first-ever Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting in Strasbourg, France from July 16-20, 2025. The session, titled "Endovascular Robotics; the next frontier for robotic surgery," will take place on July 19th at 1:30am CEST.

The panel will be moderated by Dr. Adnan Siddiqui from the University of Buffalo and Dr. Ryan Madder from Corewell Health. CEO Harel Gadot will present an overview of the endovascular robotic market and discuss the company's LIBERTY® Endovascular Robotic System, which is currently awaiting FDA 510(k) clearance expected this quarter.